BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 01, 2023 at 05:01 pm EDT
Share
BioAtla, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 35.75 million compared to USD 28.91 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 0.77 a year ago.
For the six months, net loss was USD 63.21 million compared to USD 53.16 million a year ago. Basic loss per share from continuing operations was USD 1.33 compared to USD 1.42 a year ago.
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
BIOATLA, INC. 
